Patrick Dorr

1.9k total citations · 1 hit paper
17 papers, 1.4k citations indexed

About

Patrick Dorr is a scholar working on Infectious Diseases, Virology and Immunology. According to data from OpenAlex, Patrick Dorr has authored 17 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Infectious Diseases, 9 papers in Virology and 7 papers in Immunology. Recurrent topics in Patrick Dorr's work include HIV Research and Treatment (9 papers), HIV/AIDS drug development and treatment (8 papers) and Immune Cell Function and Interaction (7 papers). Patrick Dorr is often cited by papers focused on HIV Research and Treatment (9 papers), HIV/AIDS drug development and treatment (8 papers) and Immune Cell Function and Interaction (7 papers). Patrick Dorr collaborates with scholars based in United Kingdom, United States and Germany. Patrick Dorr's co-authors include Manos Perros, Mike Westby, Julie Mori, Caroline Smith‐Burchnell, Malcolm Macartney, Paul Griffin, Anthony Wood, Carolyn Napier, Duncan Armour and Blanda Stammen and has published in prestigious journals such as Nature Medicine, Journal of Virology and Journal of Medicinal Chemistry.

In The Last Decade

Patrick Dorr

16 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

2005 909 citations Patrick Dorr, Mike Westby et al. Antimicrobial Agents and Chemotherapy profile →

Peers

Countries citing papers authored by Patrick Dorr

Since Specialization

Citations

This map shows the geographic impact of Patrick Dorr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Dorr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Dorr more than expected).

Fields of papers citing papers by Patrick Dorr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Dorr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Dorr. The network helps show where Patrick Dorr may publish in the future.

Co-authorship network of co-authors of Patrick Dorr

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Dorr. A scholar is included among the top collaborators of Patrick Dorr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Dorr. Patrick Dorr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study 2025 ·Nature Medicine ·Moti Ramgopal, Jacob Lalezari, (unknown), (unknown), Tanaya R. Vaidya, Fei Zhou, (unknown), Patrick Dorr, Nael M. Mostafa, María L. Alcaide, Franco Felizarta, Jean‐Pierre Routy	0
2	Diversity of CFTR variants across ancestries characterized using 454,727 UK biobank whole exome sequences 2024 ·Genome Medicine ·Justin E. Ideozu, Mengzhen Liu, Bridget Riley‐Gillis, (unknown), Fedik Rahimov, Preethi Krishnan, Rakesh Tripathi, Patrick Dorr, Hara Levy, Ashvani K. Singh, Jeffrey F. Waring, Aparna Vasanthakumar	10
3	Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19 2022 ·PLoS Pathogens ·D. Clark Files, Frank Tacke, (unknown), Patrick Dorr, (unknown), William G. Powderly	19
4	Biomarkers for the clinical development of antiviral therapies 2020 ·Cytometry Part B Clinical Cytometry ·Teresa I. Ng, Patrick Dorr, Preethi Krishnan, Daniel E. Cohen, Susan Rhee, (unknown), Melanie C. Ruzek, Federico Mensa, Warren M. Kati	2
5	Real‐world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1‐ and 4‐infected patients with diverse comorbidities and comedications: A pooled analysis of post‐marketing observational studies from 13 countries 2019 ·Journal of Viral Hepatitis ·Péter Ferenci, Stefan Bourgeois, Peter Buggisch, Suzanne Norris, Manuela Curescu, Dominique Larrey, Fiona Marra, H. O. Kleine, Patrick Dorr, (unknown), Eric D. Crown, (unknown), David Back, Robert Flisiak	9
6	Epigenetic reprogramming in hepatitis C virus-induced liver fibrosis: DNA methylation as a biomarker to identify susceptibility 2017 ·Journal of Hepatology ·Ajithkumar Vasanthakumar, J. Wade Davis, Kenneth B. Idler, (unknown), Lee Hazelwood, Manal Abunimeh, Patrick Dorr, (unknown), (unknown), Samantha J. England, Jeffrey F. Waring	1
7	Susceptibility of HIV Type 2 Primary Isolates to CCR5 and CXCR4 Monoclonal Antibodies, Ligands, and Small Molecule Inhibitors 2011 ·AIDS Research and Human Retroviruses ·(unknown), (unknown), Marta Calado, Patrick Dorr, José Miguel Azevedo‐Pereira	8
8	An Imidazopiperidine Series of CCR5 Antagonists for the Treatment of HIV: The Discovery of N-{(1S)-1-(3-Fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798) 2010 ·Journal of Medicinal Chemistry ·Paul A. Stupple, (unknown), (unknown), Patrick Dorr, David A. Ellis, David R. Fenwick, Sébastien R. G. Galan, R. Jones, Helen J. Mason, Donald S. Middleton, Manos Perros, Francesca Perruccio, (unknown), David C. Pryde, Débora F. Rodrigues, (unknown), Peter T. Stephenson, Robert O. Webster, Mike Westby, Anthony Wood	32
9	Chapter 2 CCR5 Pharmacology Methodologies and Associated Applications 2009 ·Methods in enzymology on CD-ROM/Methods in enzymology ·(unknown), Sarah Able, Paul Griffin, (unknown), Ian James, Malcolm Macartney, (unknown), James E. Mills, Carolyn Napier, Iva Navrátilová, Manos Perros, (unknown), (unknown), Elna van der Ryst, Mike Westby, Patrick Dorr	13
10	CCR5 inhibitors in HIV-1 therapy 2008 ·Expert Opinion on Drug Discovery ·Patrick Dorr, Manos Perros	14
11	Lack of alternative coreceptor use by pediatric HIV-1 R5 isolates for infection of primary cord or adult peripheral blood mononuclear cells 2007 ·Archives of Virology ·(unknown), Patrick Dorr, Manos Perros, (unknown), Jean Leif, Katherine Luzuriaga, Paul R. Clapham	3
12	Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry 2006 ·Journal of Virology ·Mike Westby, Caroline Smith‐Burchnell, Julie Mori, Marilyn Lewis, Michael Mosley, (unknown), Patrick Dorr, Giuseppe Ciaramella, Manos Perros	273
13	Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: Effects of viral diversity, target cell and receptor density 2005 ·Antiviral Research ·(unknown), Paul J. Peters, Wendy Sullivan, Patrick Dorr, Manos Perros, Paul R. Clapham	23
14	Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity breakdown → 2005 ·Antimicrobial Agents and Chemotherapy ·Patrick Dorr, Mike Westby, (unknown), Paul Griffin, (unknown), Malcolm Macartney, Julie Mori, (unknown), Caroline Smith‐Burchnell, Carolyn Napier, Rob Webster, Duncan Armour, David A. Price, Blanda Stammen, Anthony Wood, Manos Perros	909
15	Novel Small-Molecule Inhibitors of RNA Polymerase III 2003 ·Eukaryotic Cell ·(unknown), Jing Pan, (unknown), Deborah R. Wysong, Ronald K. Blackman, Christine Bulawa, Alexandra E. Gould, Timothy D. Ocain, Lawrence R. Dick, (unknown), Patrick Dorr, Tanya Parkinson, (unknown), Daniel Kornitzer, Ziva Weissman, Ian M. Willis, Karen McGovern	68
16	Components of the wall and capsule of Bacillus megaterium NCIB 7581 1993 ·Journal of General Microbiology ·Alistair H. Bishop, C.W.I. Douglas, Patrick Dorr, Philip J. White	2
17	Cyanide oxygenase and cyanase activities ofPseudomonas fluorescensNCIMB 11764 1989 ·FEMS Microbiology Letters ·Patrick Dorr, Christopher J. Knowles	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact